Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | South Carolina-based IMCS Scientists Awarded Patent for Enzyme Engineering TechnologyBy: IMCS IMCS has been leading the way in the development of recombinant beta-glucuronidase enzymes (also β-glucuronidase) "These patents exemplify the technical competencies at IMCS and continue to demonstrate its leading role in enzyme engineering," "As a long-time user of IMCS' recombinant beta-glucuronidase, I am excited in novel products that help move the industry forward," said T. Scott Kephart, Ph.D., President at Quasar, who is not involved in this research. "Recombinant enzymes have enormous impact in the clinical, forensic, academic, and biopharmaceutical fields. As a country reeling from the effects of the opioid crisis, the use of novel enzymes for the accurate quantification of medications and drugs of abuse is crucial for effective patient care." IMCS patented enzyme technologies make it possible to design enhanced beta-glucuronidases that detect a wide range of drugs with high sensitivity and specificity. These enzymes enable clinical labs to meet the increased demand for more sensitive tests by improving the detection of low concentrations of drugs in a patient's urine or blood sample. For additional information, contact IMCS at https://imcstips.com/ About IMCS Integrated Micro-Chromatography Systems, Inc is a privately held biotechnology company that strives to address the growing needs of clinical and research laboratories through innovative technologies and custom solutions designed to increase testing efficiency. IMCS creates, manufactures, and distributes next-generation biotechnology products to clinical and forensic toxicology, academic research facilities, US government agencies, and health science companies around the world. End
|
|